

MAY 15, 2024

Supporting the Translational Pipeline

Rebecca Tamarchak

ICRP Annual Meeting 2024



OICR was created in 2005 to accelerate the translation of cancer research discoveries in Ontario

OICR directs Ontario cancer research funding to areas of greatest opportunity – capitalize on cancer research strengths, address gaps in translational research capacity – to make Ontario a major global address for cancer research, improve cancer patient outcomes and benefit the local economy.

OICR currently receives core funding of \$72M CAD/year from Ontario's Ministry of Colleges and Universities



OICR conducts and enables world-class cancer research in Ontario by investing in three areas:

Strengthening Ontario's **capacity** to undertake world-class cancer research

Driving **collaborative, translational** cancer research

Working with partners to facilitate the **advancement, commercialization** and **adoption** of cancer innovations into clinical practice.

Our approach to supporting the translational pipeline

Unique features

- Ontario-wide scope
- Build/sustain critical translational research infrastructure
- Independent: arms-length from government, not connected to a hospital

Research funding model

- Active project management and oversight
- Patient Partnership
- Equity, Diversity and Inclusion
- Translational pathway planning – commercialization and implementation planning

OICR priorities




Overall emphasis on **earlier cancer detection**, which offers the best opportunity to stop cancer before it can take hold, grow more complex and spread.



OICR collaborates with the commercialization group FACIT to drive cancer research to benefit patients and the Ontario economy.

Building Ontario's pathway for translating cancer IP

Together, we **conduct and enable** world-class cancer research, while **investing** in cancer **IP and entrepreneurs**



Many of Ontario's largest **commercial health research successes** have arisen from OICR and FACIT



Translation of discovery into transformative care: the Ontario Health – OICR learning partnership

Building a more effective cancer care system in Ontario through policy solutions to facilitate the evaluation and adoption of new research

Ministry of Colleges & Universities



ACCELERATING CANCER RESEARCH
DISCOVERIES FOR PATIENTS AND THE
ONTARIO ECONOMY

RAPIDLY TRANSFORMING
EVIDENCE AND KNOWLEDGE
INTO PRACTICE




Ontario Health
Cancer Care Ontario

Ministry of Health

CANCER GENETICS IN ONTARIO TODAY

OPPORTUNITY TO HARMONIZE & CENTRALIZE

- Hereditary cancer
~10% of all cancer
- Unique lifecycle,
various
checkpoints of
opportunity
- Valuable families
to inform all cancer
patients




Hospital based clinical genetic testing labs not involved in research = lost opportunity

OPPORTUNITIES

20

ONTARIO GENERAL
AND SPECIALIZED
GENETICS CLINICS



9

ONTARIO LABS
GERMLINE TESTING
FOR HEREDITARY
CANCER



76

GENES ON
STANDARDIZED
PANEL
(APRIL 1, 2021)



CHALLENGES

CARRIERS DIFFICULT
TO ASCERTAIN &
TRACK

INEQUITABLE
ACCESS TO
RESEARCH

LACK OF
STANDARDIZATION:

ACCESSIONING
BIOINFORMATICS
SURVEILLANCE
INTERPRETATION
REPORTING

DATA SHARING
CHALLENGES

Ontario Hereditary Cancer Research Network

A unified hereditary cancer registry will improve patient care and cancer research in Ontario

IMPROVE CLINICAL CARE

- Coordinated care
- Patient advocacy
- Cascade testing
- Diagnostic development
- Personalized medicine



CONNECT TO RESEARCH

- Clinical trials
- VUS reclassification
- Gene discovery, genomics, computational biology




COMMUNITY BUILDING

- Eliminate barriers
- Collaboration and data sharing
- Improve access to experts



BUILD ON EXISTING DATA

- Information pipelines, health data
- Imaging, high-risk screening
- Tumour genomics





Funding for the Ontario Institute for Cancer Research
is provided by the Government of Ontario

